Consolidated statements of changes in equity

 View as excel [XLS - 35KB]


  Attributable to holders of the parent          
  Issued
share
capital
R'000
  Share
premium
R'000
  Non-
distributable
reserves
R'000
  Retained
income
R'000
  Total
attributable
to ordinary
shareholders
R'000
  Non-
controlling
interests
R'000
  Total
R'000
 
As at 1 July 2013 16 861   524 788   467 433   2 762 300   3 771 382   129 801   3 901 183  
Share issue 49   7 263           7 312       7 312  
Movement in treasury shares (32)   (21 131)           (21 163)       (21 163)  
Movement in share-based payment reserve         8 825       8 825       8 825  
Acquisition of non-controlling interests in Ayrton Drug Manufacturing Limited             (69)   (69)   (174)   (243)  
Total comprehensive income         (46 174)   (832 533)   (878 707)   (3 748)   (882 455)  
   Loss for the year             (832 533)   (832 533)   3 764   (828 769)  
   Other comprehensive income         (46 174)       (46 174)   (7 512)   (53 686)  
Dividends             (145 010)   (145 010)   (7 301)   (152 311)  
Share issue expenses incurred by subsidiary         (3 669)       (3 669)       (3 669)  
Balance at 30 June 2014 (audited) 16 878   510 920   426 415   1 784 688   2 738 901   118 578   2 857 479  
Share issue 10   2 018           2 028       2 028  
Movement in share-based payment reserve         16 098       16 098       16 098  
Acquisition of non-controlling interests in Ayrton Drug Manufacturing Limited             (31)   (31)   (101)   (132)  
Total comprehensive income         62 487   197 932   260 419   (330)   260 089  
   Profit for the year             197 932   197 932   877   198 809  
   Other comprehensive income         62 487       62 487   (1 207)   61 280  
Disposal of non-controlling interest in Bioswiss (Pty) Limited                     (14 101)   (14 101)  
Dividends                     (4 537)   (4 537)  
Balance at 30 June 2015 (audited) 16 888   512 938   505 000   1 982 589   3 017 415   99 509   3 116 924